AI Article Synopsis
- The meta-analysis explored the link between the butyrylcholinesterase (BCHE) K variant and the risk of Alzheimer's disease (AD), finding a significant association overall.
- The study revealed that the BCHE K variant was notably linked to AD risk in Asian populations and particularly with late-onset AD, while showing no significant association in Caucasians or early-onset AD.
- Additionally, the presence of the APOE ε4 allele was found to substantially increase AD risk for both BCHE K carriers and non-carriers.
Article Abstract
Background: Although many studies have estimated the association between the butyrylcholinesterase (BCHE) K variant and Alzheimer's disease (AD) risk, the results are still controversial. We thus conducted this meta-analysis.
Material/methods: We searched NCBI, Medline, Web of Science, and Embase databases to find all eligible studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.
Results: We found a significant association between BCHE K variant and AD risk (OR=1.20; 95% CI 1.03-1.39; P=0.02). In the stratified analysis by ethnicity, we observed a significant association between BCHE K variant and AD risk in Asians (OR=1.32; 95% CI 1.02-1.72; P=0.04). However, no significant association between BCHE K variant and AD risk in Caucasians was found (OR=1.14; 95% CI 0.95-1.37; P=0.16). When stratified by the age of AD onset, we found that late-onset AD (LOAD) was significantly associated with BCHE K variant (OR=1.44; 95% CI 1.05-1.97; P=0.02). No significant association between BCHE K variant and early-onset AD (EOAD) risk was observed (OR=1.16; 95% CI 0.89-1.51; P=0.27). Compared with non-APOE ε4 and non-BCHE K carriers, no significant association between BCHE K variant and AD risk was found (OR=1.11; 95% CI 0.91-1.35; P=0.30). However, APOE ε4 carriers showed increased AD risk in both non-BCHE K carriers (OR=2.81; 95% CI 1.75-4.51; P=0.0001) and BCHE K carriers (OR=3.31; 95% CI 1.82-6.02; P=0.0001).
Conclusions: The results of this meta-analysis indicate that BCHE K variant might be associated with AD risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444173 | PMC |
| http://dx.doi.org/10.12659/MSM.892982 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Association Study of Acetylcholinesterase () and Butyrylcholinesterase () Variants in Sudden Infant Death Syndrome (SIDS).
Genes (Basel)
December 2024
Institute of Legal Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Background: Sudden infant death syndrome (SIDS) is the leading cause of death among infants aged between one month and one year. Altered enzyme activities or expression of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) have been observed in SIDS patients that might lead to disturbed autonomic function and, together with other risk factors, might trigger SIDS. To explore the contribution of AChE and BChE from a genomic viewpoint, we sought to investigate the association between SIDS and selected single nucleotide polymorphisms (SNPs) in the and genes.
View Article and Find Full Text PDFA novel BCHE frameshift mutation in a Chinese woman with butyrylcholinesterase deficiency: A case report and literature review.
Medicine (Baltimore)
October 2024
Department of Cardiovascular, People's Hospital of Changshou Chongqing, Chongqing, China.
Rationale: Congenital butyrylcholinesterase deficiency (BCHED) is a rare autosomal recessive genetic disorder caused by a pathogenic mutation in the BCHE gene. Patients with BCHED may experience prolonged apnea or even death after the application of drugs such as succinylcholine. We aimed to identify the genetic basis of disease in a patient presenting with butyrylcholinesterase deficiency in order to confirm the diagnosis, expand BCHE gene mutation spectrum, and elucidate potential genotype-phenotype associations to inform management.
View Article and Find Full Text PDFThe clinical and genetic spectrum of paediatric speech and language disorders.
Brain
October 2024
Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Article Synopsis
- Speech and language disorders have a significant genetic component, but research specifically focusing on linguistic differences as unique conditions has been limited.
- An analysis of over 52,000 pediatric individuals revealed that these disorders are most common between ages 2 and 5, with only 12% of stuttering cases accurately coded in medical records.
- The study identified key genetic disorders linked to these disorders and found notable associations between specific genetic variants and conditions like aphasia and speech delays related to hearing loss.
Gulf war illness: a tale of two genomes.
BMC Res Notes
August 2024
Department of Medicine, University of California, San Diego, La Jolla, 92093, CA, U.S.A.
Introduction: Gulf War illness (GWI) is an environmentally-triggered chronic multisymptom illness typified by protean symptoms, in which mitochondrial impairment is evident. It has been likened to accelerated aging. Nuclear genetics of detoxification have been linked to GWI.
View Article and Find Full Text PDFOnset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers.
BMC Neurol
April 2024
Dementia Research Centre, Institute of Neurology, London, UK.
Background: The authors sought to examine the impact of the K-variant of butyrylcholinesterase (BCHE-K) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers.
Methods: Patients aged 50-74 years with cerebrospinal fluid (CSF) biomarker-confirmed AD, were recruited to clinical trial (NCT03186989 since June 14, 2017). Baseline demographics, disease characteristics, and biomarkers were evaluated in 45 patients according to BCHE-K and APOE4 allelic status in this post-hoc study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!